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Abstract 
Background: Focal colorectal uptake in 18FDG-PET/CT may be associated with a malignancy and can be quantified. 
This provides the basis for an automatic trigger threshold above which cases are flagged for colonoscopic evaluation 
and below which for individual assessment.
Purpose: To determine the lowest maximum standard uptake (SUVmax) in colorectal cancer that could be used as a 
threshold to trigger endoscopic evaluation and to evaluate whether the SUVmax needs to be further normalised to a 
priori known extrinsic factors.
Methods: The SUVmax was measured in 54 colorectal carcinomas and correlated with gender, age, blood glucose 
level, injected activity, body mass index and time to scan using t test or correlation coefficients (Pearson or Spearman, 
according to distribution).
Results: There was no correlation between SUVmax and any of the extrinsic factors mentioned above. The lowest 
SUVmax value was 5 [mean ± SD (range): 11.1 ± 4.8 (5.0–24.6)].
Conclusion: In contrast to most other screening techniques, semi-automation in colorectal screening seems pos-
sible with PET/CT. This opens the door for further study into the feasibility of automated screening. Independent 
from extrinsic factors, an SUVmax ≥5.0 in a focal colorectal uptake in 18FDG-PET/CT should automatically trigger for 
endoscopic evaluation, if not contraindicated. Cases with SUVmax <5 should be assessed individually before referral for 
endoscopy. Thus, more interpretation time could be spent on those cases with a lower uptake and more ambiguous 
diagnosis.
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Background
18FDG-PET/CT is widely used in the detection and 
monitoring of most cancer entities. It provides images of 
malignant cell proliferation via the glucose uptake fuel-
ling it thus combining glucose metabolism data with 
morphology. It is already successfully used for staging, 
restaging and follow-up, changing therapeutic manage-
ment in up to 36 % of cases [1] and avoiding future tests 
in up to 91 % [2]. It was proposed for screening as early as 
1997 [3] closely in line with CT colonography [4] and MR 
colonography [5]. The technique has progressed since 
that time and continues to do so. The only organs that 
remain a diagnostic challenge for 18FDG-PET/CT are the 
colon, breast, stomach, urinary tract and the carcinomas 
for which there are specific tumour markers [prostate-
specific antigen (PSA), alpha fetoprotein (AFP), calci-
tonin, chromogranin A].
There have been no large studies to compare PET/CT 
with colonoscopy with respect to accuracy in the screen-
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PET/CT has three main advantages over colonoscopy 
and CT/MR colonography:
1. It is completely non-invasive—it avoids cleansing and 
distension of the colon and as such is more readily 
accepted than colonoscopy by the population.
2. It allows for early detection of extra-colonic diseases, 
a valuable side-benefit.
3. Its analysis can be more easily automated due to the 
3D digitisation of glucose metabolism with high con-
trast between focal accumulation and normal distri-
bution.
The latter advantage requires the definition of a 
threshold to automatically trigger further diagnosis, 
by endoscopic evaluation in this case. In contrast to a 
cut-off, which separates benign and non-benign and 
thereby defines the outcome for both sides, a threshold 
value automatically triggers the outcome only for the 
group above the threshold. Individual and subjective 
analysis is then applied to those cases that fall below 
the threshold. This is already used in PSA screening in 
which transrectal palpation and/or ultrasound deter-
mines the decision to investigate PSA-negative carci-
nomas [6]. Safeguards must be devised for the group 
below the threshold, in order to minimise false nega-
tives, in particular to facilitate the detection of small 
tumours.
The maximum standard uptake value (SUVmax) is cur-
rently the most promising candidate to trigger further 
diagnosis and therapy as it reflects tumour vitality. Thus, 
the SUV is used to refine chemo- and radiation therapy 
according to vitality—the rationale behind interim stag-
ing with PET/CT [7, 8].
A threshold used to trigger colonoscopic evaluation for 
the majority of cancers should be independent of extrin-
sic effects. Thus, the purpose of the study was (a) to eval-
uate whether the SUVmax requires further normalisation 
and (b) to determine the lowest SUVmax to warrant auto-
mated referral for endoscopy.
Methods
In a retrospective study approved by the Institutional 
Ethics Committee, patients with histologically proven 
colorectal cancer imaged with 18FDG-PET/CT before the 
onset of therapy were retrieved from a database search. 
Any patients with histologically proven colorectal can-
cer but a negative PET/CT would thus also have been 
included in the study.
PET/CT was performed 75 ± 14 min after injection of 
329 ± 46 MBq FDG on a 16-slice PET/CT (Biograph 16, 
Siemens Medical Solutions) from the skull base through 
to the mid-thigh in 7–8 table positions each of 3-min 
duration. For attenuation correction, a low-dose (<1 mSv) 
CT was performed with 10 mAs, 120  kV, 16 ×  1.5  mm 
collimation, 0.42  s tube rotation time and 6 mm/s table 
feed. CT images were reconstructed with 2.5-mm-thick 
slices. PET images were iteratively reconstructed using 
ordered subset expectation maximisation (OSEM) with 6 
iterations, 4 subsets, 5  mm full width at half maximum 
(FWHM) smoothing and 168  ×  168 reconstruction 
matrix for 70-cm gantry.
The SUVmax was measured in the colorectal tumour. 
The SUVmax is normalised for injected activity per body 
weight according to the formula: SUVmax  =  maximum 
VOI activity (Bq/ml)/dose injected per patient’s weight 
(Bq/g) with g = ml for a tissue density of 1 g/ml.
The association of SUVmax with T-stage, gender, age, 
blood glucose level, injected activity and time to scan (dis-
tribution phase) was analysed using t test or correlation 
coefficients (Pearson or Spearman according to distribu-
tion). Statistical analysis was performed using the standard 
software package SPSS Inc., version 16.0, Chicago, USA.
Results
Fifty-four patients (16 female, 38 male) aged 43–91 years 
(mean: 67 ± 10 years) were included in the study. Refer-
ring reasons for PET/CT were initial staging (n  =  35) 
(Fig.  1), staging of another carcinoma with incidental 
detection of colorectal cancer as second cancer (n = 17) 
(Figs. 2, 3) and search for the primary cancer in cancer-
of-unknown primary (CUP) syndrome (n = 2).
In the tested ranges, there was no correlation between 
SUVmax and the extrinsic factors listed in Additional 
file  1: Table  S1 [SUVmax vs. age (Pearson correlation 
coefficient = 0.074), SUVmax vs. body mass index (Pear-
son correlation coefficient = 0.148), SUVmax vs. injected 
activity (Pearson correlation coefficient  =  0.185), SUV-
max vs. glucose level (Spearman correlation coeffi-
cient =  0.047) and SUVmax vs. time to scan (Spearman 
correlation coefficient  =  −0.004)]. The SUVmax did not 
significantly differ among the various T-stages (all p val-
ues >0.05) (Fig. 4). The lowest p value was 0.07 between 
stages T2 and T4.
The lowest SUVmax value was 5 [mean ±  SD (range): 
11.1 ± 4.8 (5.0–24.6)] (Additional file 1: Table S1).
Discussion
Semi-automation in colorectal screening seems feasi-
ble with PET/CT. A focal colorectal FDG accumulation 
with SUVmax ≥5 should automatically trigger a refer-
ral for colonoscopy leaving the cases with SUVmax <5 
for individual interpretation. Even if the SUVmax varies 
with scanner type, the semi-automation approach seems 
robust; a possible scanner-related shift of this threshold 
value will be compensated by subjective interpretation 
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as for any other focal colorectal uptake below the trigger 
threshold.
Normalisation to a priori known extrinsic factors
We found no correlation between the SUVmax and a 
priori known extrinsic factors that could bias the SUV-
max measurements (Additional file  1: Table  S1). This 
suggests that the SUVmax does not need to be further 
normalised for these a priori known extrinsic factors. 
The lack of correlation between the SUVmax and the 
time to scan suggests that the SUVmax is independent 
of the time of scanning in the tested range 59–112 min 
(mean: 75  ±  14  min) after injection. Further study is 
needed using dynamic PET to test intra-individually at 
30, 60, 90 and 120 min to ascertain which time interval 
between injection and imaging is optimal for the detec-
tion of malignant colorectal uptakes. It has recently 
been found that normalisation to the blood pool in 
the aorta provides a means of correcting for scan time 
dependence [9]. This requires further verification. The 
lack of correlation between the SUVmax and activity in 
the tested range 94–395  MBq (mean: 329  ±  46  MBq) 
suggests that the activity can be reduced, possibly inde-
pendent of weight, to 200 MBq. This is of interest in sit-
uations where PET/CT may be offered to asymptomatic 
individuals instead of screening colonoscopy where 
endoscopy is contraindicated, refused or not possible to 
complete.
Benefit vs. radiation risk of PET/CT
To be justified, the benefit of PET/CT in early detec-
tion must compensate for its radiation risk. With 
200 MBq activity the total radiation exposure can be 
reduced to less than two times natural background radi-
ation (200  MBq  ×  6.7  mSv/350  MBq [10]  +  0.8  mSv 
[11] = 4.6 < 2 × 2.4 = 4.8 mSv, assuming a linear relation-
ship between MBq and mSv if 350 MBq results in 6.7 mSv 
[10]). The dose issue is especially significant if PET/CT 
is used for screening before the onset of symptoms in 
healthy subjects. The purely hypothetical [12] and delayed 
radiation risk is compensated if PET/CT detects 3 % of the 
colorectal cancers which occur in 0.9 % of cases (colono-
scopic prevalence in a screening setting) [13] (x % sensi-
tivity × 0.9 % prevalence >0.005 %/mSv [14] radiation risk 
× 4.8 mSv radiation exposure; with x % >3 %). In this cal-
culation of the minimum required sensitivity (x % -> 3 %), 
the concurrent detection of extra-colonic cancer entities 
and advanced adenomas, as well as other serious con-
ditions such as cardiovascular disease, were not taken 
into account thus underestimating the overall benefit of 
Fig. 1 Colorectal cancer with solitary hepatic and lung metastases in the initial staging. Maximum intensity projection (MIP) of PET captured in the 
coronal projection of the 360°-rotation (a), axial slices of PET (b), CT (c) and PET/CT (d) and colonoscopy (e). The rotating MIPs of PET, here captured 
in coronal projection (a), enable clear depiction of colorectal cancer, here with a maximum standardised uptake value (SUVmax) of 6.9, at the first 
view in contrast to CT (c) and colonoscopy (e) both of which are invasive, require bowel preparation and time consuming step-by-step analysis
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Fig. 2 Colorectal cancer (arrow) as an incidental finding in the PET/CT restaging of oesophageal cancer with new lymph node and hepatic metas-
tases. Maximum intensity projection (MIP) of PET captured in the coronal projection of the 360°-rotation (a), axial slices of PET (b), CT (c) and PET/
CT (d) and colonoscopy (e). Note that the 18F-FDG-filled bladder can obscure carcinomas on the coronal maximum intensity projection (MIP) (a). 
Rotating MIPs or scrolling through axial PET slices (b) is mandatory to detect such carcinomas. The colorectal cancer, here with an SUVmax of 9.7, is 
clearly depicted on the axial PET images (b) in contrast to CT (c)
Fig. 3 Colorectal cancer (arrow) in the initial staging. Maximum intensity projection (MIP) of PET captured in the coronal projection of the 360°-rota-
tion (a), axial slices of PET (b), CT (c) and PET/CT (d) and colonoscopy (e). As in Fig. 2, rotating the maximum intensity projection (MIP) or scrolling 
through axial PET slices (b) is mandatory to detect carcinomas behind the urinary bladder. PET clearly depicts the colorectal cancer, here with an 
SUVmax of 6.1
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PET/CT. Furthermore, there is a 10- to 40-year delay [15] 
between the hypothetical induction and development of 
radiation-induced cancer; the natural history of a missed 
cancer, had PET/CT not been performed, is more severe 
than the natural history of a hypothetical and delayed 
induced cancer, had PET/CT been performed. Addition-
ally, the benefit-to-risk ratio of PET/CT increases with age 
due to the decreasing radiation risk and increasing inci-
dence of cancer. This is in contrast to colonoscopy, where 
the rate of complication increases with age, while the 
prophylactic meaning of a polypectomy decreases. This 
is especially relevant as colorectal screening is recom-
mended for individuals up to 70 years of age [16].
Determination of the optimum SUVmax threshold
In our study, we found the minimum SUVmax in 54 colo-
rectal carcinomas to be 5 thus determining the threshold. 
There are only a few studies which showed an SUV-
max lower than 5 for colorectal cancer. Sarikaya et  al. 
[17] reported four carcinomas that were detected with 
SUVmax <4.5, of which three were mucinous. Peng et al. 
[18] reported a range in SUVmax from 3.1 to 28 which 
included two mucinous carcinomas. The low cellularity 
of mucinous carcinomas may explain the low SUVmax. 
A meta-analysis regarding the SUVmax of colorectal can-
cer is not possible because the SUVmax was not always 
listed for each carcinoma. When SUVmax is used as the 
sole trigger, and not in combination with other factors, 
an SUVmax threshold of 5 would cover 96 % (215/224) of 
FDG-positive colorectal cancers (Figs. 1, 2, 3, 4) [17–31], 
leaving only 4  % of positive cases requiring individual 
interpretation.
False negatives (FN) (carcinomas)
Besides the 4 % of PET-positive colorectal cancer cases that 
fall below the threshold, some cancer cases are completely 
PET negative. The rate of PET-negative cancer cases may be 
at least 5 % as suggested by studies looking at all patients 
who underwent PET/CT followed by colonoscopy within 
a short period of time [25, 30, 32]. On the other hand, the 
miss-rate of optical colonoscopy can be estimated at a 
worst case of 2.9 %, assuming that all 2.9 % of the so-called 
interval cancers occurring within 5 years of a negative colo-
noscopy were missed and not newly developed [33].
The issue of false negatives must be viewed in context. 
The vast majority of the German population currently 
does not come forward for screening due in large part 
to the invasive nature of colonoscopy. Between 2002 and 
2008, 2,821,392 screening colonoscopies were performed 
across Germany which represents 15.5 and 17.2 % of all 
eligible men and women, respectively, from the age group 
55–74 years [13]. Thus, approximately 80 % of the target 
group did not take advantage of the colonoscopy screen-
ing programme during this 6-year screening interval. 
Although the acceptance rate is higher in some other 
countries, such as the US, there is a widespread reluc-
tance on the part of the population to come forward for 
colonoscopy-based screening. Shortcomings in alterna-
tive screening techniques must be balanced against the 
significant number of tumours which progress to a more 
advanced stage due to this very low acceptance of colo-
noscopy screening. PET/CT should not replace colonos-
copy screening in the minority of individuals who assent, 
but provide an attractive alternative for the majority who 
refuse. Thus, if colonoscopy is refused, PET/CT needs to 
be compared with faecal occult blood test (FOBT) and 
not with colonoscopy.
False positives (FP)
FDG-enriched stool in the caecum is the most common 
cause of false-positive FDG accumulation [11]. FDG 
excretion into the small bowel and accumulation in the 
caecum during the 60-min interval between injection 
and imaging may explain this observation. The typical 
location in the caecum in conjunction with centric dis-
tribution and air-typical CT values, which indicate air 
inclusions, helps to differentiate FDG-enriched stool 
from a wall-adherent eccentric mass. Although Van Heoij 
et  al. [31] recently found that the SUVmax in 404 focal 
colorectal uptakes was significantly higher for cancer 
(p < 0.001) than for all other types of lesions (advanced 
adenoma, non-advanced adenoma and benign lesions), 
Keyzer et  al. [34] showed that the SUVmax alone does 
not differentiate true- from false-positive colorectal FDG 
foci. The metabolic volume also failed to differentiate TP 












































Fig. 4 Maximum standard uptake value (SUVmax) in relation to the 
TNM stage. All values were greater than 5, and there was no cor-
relation between the SUVmax and the tumour stage in the 27 cases 
with available TNM stage data (Additional file 1: Table S1). [Note: The 
patient with the minimum SUVmax = 5 (Nr. 32 in Additional file 1: 
Table S1) is not included. The operation was performed outside the 
TNM stage and the data were thus not available]
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As the SUVmax in premalignant/malignant and physio-
logical/benign colorectal FDG accumulation is indistinct, 
the clear separation (cut-off) between TP and FP seems 
to be unattainable with SUVmax alone. We therefore 
defined the trigger as automating the decision above a 
threshold only (semi-automated analysis). Given the rela-
tively low prevalence of focal colorectal uptakes (3.6  %) 
but the relatively high risk of these being malignant or 
premalignant (68 %) [36], the benefit of maximising the 
sensitivity with semi-automated analysis seems to justify 
a lower specificity with more FPs. If colonoscopy is the 
worst consequence of an FP, these patients would not be 
disadvantaged compared to their outcome had they taken 
up the current screening programme [16, 37]. In compar-
ison to colonoscopy, the 1.5 % rate of FP in PET/CT [36] 
with consecutive colonoscopy is far lower than the 26.5 % 
rate of false-positive polypectomies, several polypecto-
mies per person not counted [13].
Partial volume effects: a drawback of digitisation
Averaging within a volume pixel (voxel) of a finite edge 
length is a drawback of digitisation. Smaller lesions in the 
range of only view voxels might not be visible due to spa-
tial and temporal averaging within one voxel (partial vol-
ume artefacts) [38]. The resultant blurring might reduce 
the overall contrast so that the lesion is not delineated. 
However, a very high uptake—the so-called hot spot phe-
nomenon, as known from melanoma—might compen-
sate for a larger voxel size and even depict lesions within 
the range of the voxel resolution [currently: 95  mm3 
(=0.095 ml) based on 400 × 400 matrix reconstruction]. 
However, this potential inferiority in voxel resolution 
compared to optical colonoscopy might be compensated 
by a shorter screening interval (e.g. 5  years as for CT 
colonography [37]). This may be completely unnecessary 
when the long lead time of 10 years in the adenoma-to-
carcinoma sequence is taken into account [39–42] and 
the fact that therapy in asymptomatic (lower stage) colo-
rectal cancer is mostly curative. Furthermore, it must 
be emphasised that lower voxel resolution can easily be 
compensated for by a shorter screening interval, in con-
trast to a lower screening acceptance rate which cannot 
be compensated for.
Extrapolation to advanced adenoma
There is some evidence that PET/CT failed to detect 
around half of cases with advanced adenoma [43]. The 
study was performed between 2000 and 2009 using 
now outdated PET and PET/CT technology. Since then, 
the spatial resolution has improved from 4.5  mm to 
almost 2  mm today, for example. In an interval screen-
ing programme, it is the accuracy of the programme and 
not of the single test which matters. Furthermore, the 
consequence of a missed tiny adenoma is unclear if the 
cancer can still be curatively resected at the consecutive 
screening, if indeed the adenoma develops to cancer at 
all. The mismatch in prevalence between advanced ade-
noma (6.4 %) and colorectal cancer (0.9 %) [13] suggests 
that not all advanced adenomas proceed to cancer. It is 
assumed that a patient with advanced adenoma at age 
55–65 has a greater than 50 % chance of developing colon 
cancer [44]. The potential lack in screening sensitivity 
may be compensated by reducing the interval between 
examinations (for example from 10 to 5  years as pro-
posed for CT colonography [37]), but a low screening 
acceptance rate cannot be compensated.
To date, we have neither included advanced adenoma 
nor correlated the FDG uptake with the KI 67 index as 
markers for proliferation. We measured FDG uptake 
versus TNM stage, however, and found no correlation 
(Fig.  4). Pending further study, we might extrapolate 
that the trigger SUVmax ≥5 is also valid for advanced 
adenoma, depending on the growth rate. The hypothesis 
that the SUVmax correlates with the growth rate seems 
correct; glucose provides the energy for proliferation 
and is supported by the relationship between pre-oper-
ative 18FDG uptake and epidermal growth factor recep-
tor [45]. Also, 18FDG-PET detects all cancers in patients 
with familial adenomatous polyposis [46]. This is still 
speculative, however, pending a larger study. Recently, 
Na et al. [47] proposed an SUVmax = 5.8 as optimal cut-
off to identify a malignancy or high-grade dysplasia but 
warned that colonoscopy should be performed above 
an SUVmax = 2.5 to avoid missing a malignancy or high-
grade dysplasia. This is in line with the semi-automation 
we propose: an SUVmax ≥5 should automatically trigger a 
referral for colonoscopy leaving the cases with SUVmax <5 
for individual interpretation.
Case for PET/CT screening
A great deal of expertise and resources are currently 
invested in establishing, testing and improving mono-
organ screening methods. Screening programmes are 
currently in place for the early detection of oncological, 
cardiovascular and metabolic diseases including prostate, 
lung, colorectal, ovarian [48] and breast cancer, as well as 
arteriosclerosis, aortic aneurysm and osteoporosis. PET/
CT offers the possibility of replacing most mono-organ 
screening methods with a single multi-organ screening 
exam. A single PET/CT screening appointment lasting 
around 1 h promises to be more accepted, efficient, effec-
tive and safe than the combined organ-specific screening 
techniques currently in use.
In addition, PET/CT is a promising candidate for semi-
automated analysis as it acquires digital data, in vivo, at 
the molecular level. In the context of colorectal cancer, 
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this cannot be said of the subjective optical interpreta-
tion at the macroscopic level required for colonoscopy. 
Although laxative-free CT colonography [49] and PET/
CT are both non-invasive and require no bowel prepara-
tion, PET/CT seems superior for multi-organ screening 
and semi- or potentially full automation of the analysis, 
as we have discussed.
Conclusion
In contrast to most other screening techniques, semi-
automation in colorectal screening seems possible with 
PET/CT. This opens the door for further study into the 
feasibility of automated screening. Independent of extrin-
sic factors, an SUVmax ≥5.0 in a focal colorectal uptake in 
18FDG-PET/CT should automatically trigger endoscopic 
evaluation, if not contraindicated. This would improve 
the experience many individuals have during the screen-
ing process itself, as well as saving the time and cost of 
detailed interpretation of colorectal screening across the 
board. Only cases with SUVmax <5.0 should be referred 
for individual assessment.
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